Cognitive Functioning Clinical Trial
Official title:
Randomized Double-blind, Placebo-Controlled, Parallel Group, Efficacy Study of AlphaBRAIN(TM) Administered Orally
The manufacturers of AlphaBRAIN(TM) claim that their product, when taken as directed, has
beneficial effects on cognition. The active ingredient in AlphaBRAIN, Huperzine A, is a
naturally occurring compound found in firmoss and also thought to be an acetylcholinesterase
inhibitor. Numerous clinical studies have been undertaken to investigate the effects of
Huperzine A on cognition and have demonstrated benefit to cognition in both individuals
diagnosed with neurodegenerative diseases as well as performance on academic tasks by
students. However, to our knowledge, there are no randomized controlled trials evaluating
the effects of AlphaBRAIN(TM) on cognition. Thus, the purpose of the current study is to
assess the effects of daily oral administration of AlphaBRAIN(TM) on cognitive functioning,
as compared to placebo, after 45 days of treatment.
1. To evaluate a single daily dose of AlphaBRAIN(TM) vs placebo given orally on the change
in a battery of standardized neuropsychological tests (see attached).
2. A secondary objective is to evaluate a single daily dose of AlphaBRAIN(TM) vs placebo
given orally on sleep.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03328520 -
WILD 5 Wellness, A 30-Day Intervention
|
N/A | |
| Completed |
NCT01720472 -
Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository
|
||
| Withdrawn |
NCT03497299 -
Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia
|
Phase 2 |